

Cat. No. MHC-HM438

**Description**


<b>Source</b>	Recombinant Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-C 03:04), Ile21-Met119(B2M) and GADGVGKSAL peptide.
<b>Accession</b>	QAV56463.1(HLA-C 03:04)&P61769(B2M)&GADGVGKSAL
<b>Molecular Weight</b>	The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

**Formulation and Storage**


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

**Background**

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

**Assay Data****Tris-Bis PAGE**

Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

**SEC-HPLC**

The purity of Human HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer is greater than 95% as determined by SEC-HPLC.